/Investor DB

Forbion — 2022 Investments

3 investments dated 2022 · listed companies and verified rows first · show all

F2Gf2g.comAug 2022 · $70M

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova Partners+4 more

Inversagoinversago.comSeries B · Oct 2022 · $35Macquired by Novo Nordisk

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsadMare BioInnovationsAmorChemGenesys CapitalJDRF T1D FundNew Enterprise Associates (NEA)Tarnagulla Ventures+2 more

PRECIRIX NVprecirix.comSeries B · Mar 2022 · $88M

Co-investorsBioMedPartnersHealthCapInkefPontifax Venture CapitalV-Bio Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.